- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Rose Gerber Discusses Cancer Survivorship's Lifelong Side Effects
As a cancer survivor, Rose Gerber, director of patient advocacy for the Community Oncology Alliance, is personally aware of the many long-term issues that can arise during survivorship. These can include physical effects like bone health and emotional issues like the fear of recurrence.
As a cancer survivor, Rose Gerber, director of patient advocacy for the Community Oncology Alliance, is personally aware of the many long-term issues that can arise during survivorship. These can include physical effects like bone health and emotional issues like the fear of recurrence.
Transcript (slightly modified)
What are the challenges with survivorship that patients are not always prepared for?
I think there’s different levels of concerns when you’re a cancer survivor. Some of them are the actual physical issues that can arise. I am a 14-year cancer survivor and I certainly faced a lot of long-term issues, whether it’s bone health, fear of recurrence, just so many issues, and of course there’s always emotional issues.
I think that when a cancer patient finishes a primary treatment, it’s a well-known fact that there’s going to be a lot of emotional issues, but what people may not understand unless they’re cancer survivors themselves is that these issues can continue on for as long as you’re alive.
In my case, I was diagnosed at an early age, so I’m very grateful to be a survivor, but at the same time, because I was diagnosed early, I have many years in front of me where I am dealing with physical and emotional side effects of survivorship.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
